Recently, it was reported that myricetin inhibits interferon-γ-induced programmed death ligand-1 (PD-L1) and indoleamine 2,3-dioxygenase 1 (IDO1) expression in lung cancer cells via the regulation of the Janus kinase/signal transducer and activator of the JAK/STAT-IRF1 transcription pathway [19]. The gene discussed is IDO1; the disease is lung cancer.